Drug Details

General Information of the Drug (ID: DR8995)
Name
Dapagliflozin
Synonyms
Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; Farxiga; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-1ULL0QJ8UC; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; 1ULL0QJ8UC; CHEMBL429910; CHEBI:85078; Dapagliflozin [USAN:INN]; BMS512148; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Forxiga (TN); CHEMBL3125458; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; 960404-48-2; Dagagflozin; (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; BMS5121458; C-aryl glucoside, 6; PubChem22435; Tube101; Dapagliflozin (USAN/INN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; cc-205; SCHEMBL157820; GLU006; GTPL4594; BDBM20880; DTXSID20905104; EX-A005; BCPP000265; AMY18541; AOB87300; ZINC3819138; BDBM50448923; CD0219; MFCD13182359; s1548; AKOS005145763; BCP9000583; BL-0052; CCG-229917; CS-0781; DB06292; EX-7214; PB11055; NCGC00250402-09; AC-24699; HY-10450; A25150; C22193; D08897; Q-3845; 432D268; Q409898; J-500392; BRD-K58160573-001-01-3; BRD-K58160573-001-05-4; 1-[3-(beta-D-Glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
    Click to Show/Hide
Molecular Type
Small molecule
Disease Type 2 diabetes mellitus [ICD-11: 5A11] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 3 mL/min/kg
Half-life
The concentration or amount of drug in body reduced by one-half in 12.2 hours
Unbound Fraction
The unbound fraction of drug in plasma is 0.09%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.7 L/kg
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H25ClO6
PubChem CID
9887712
Canonical SMILES
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
InChI
1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
InChIKey
JVHXJTBJCFBINQ-ADAARDCZSA-N
CAS Number
CAS 461432-26-8
ChEBI ID
CHEBI:85078
TTD Drug ID
D01TNW
DrugBank ID
DB06292
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Taxifolin      Larix gmelinii     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression GABPA  Molecule Info 
Pathway MAP
Up-regulation Expression JNK1  Molecule Info 
Pathway MAP
Up-regulation Expression p105  Molecule Info 
Pathway MAP
Up-regulation Expression TLR4  Molecule Info 
Pathway MAP
                    In-vivo Model Male rats were used to establish colistin-induced nephrotoxicity animal model in this study.
                    Experimental
                    Result(s)		 Combined use of taxifolin and dapagliflozin may confer a therapeutic tool for attenuation of colistin-induced nephrotoxicity.
Target and Pathway
Target(s) Sodium/glucose cotransporter 2 (SGLT2)  Molecule Info  [3]
Reactome Hexose transport Click to Show/Hide
2 Na+-dependent glucose transporters
3 Inositol transporters
WikiPathways NRF2 pathway Click to Show/Hide
2 Nuclear Receptors Meta-Pathway
3 Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4594).
Reference 2 Effect of taxifolin/dapagliflozin combination on colistin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2021 Apr 22;9603271211010906.
Reference 3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link